Barrett's esophagus: A molecular perspective

Current Gastroenterology Reports

Volumn 7, Issue 3, 2005, Pages 177-181

  Spechler, Stuart Jon ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 BIS[3 (N PIPERIDINO)PROPIONAMIDO]ANTHRACENE 9,10 DIONE; ALPHA ACTIN; CD31 ANTIGEN; CHOLECYSTOKININ B RECEPTOR; DNA; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE; PROTEIN P16; PROTEIN P53; PROTON PUMP INHIBITOR; RAF PROTEIN; RAS PROTEIN; TELOMERASE; TELOMERASE INHIBITOR; TRANSCRIPTION FACTOR CDX2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BARRETT ESOPHAGUS; BILE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CLONE; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; GENE INACTIVATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HYPERGASTRINEMIA; INTESTINE METAPLASIA; MOLECULAR BIOLOGY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN METHYLATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH ACID; TELOMERE; TUMOR SUPPRESSOR GENE;

EID: 21444446353     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-005-0031-z     Document Type: Review

References (28)

1. Spechler SJ: Barrett's esophagus. N Engl J Med 2002, 346:836-842.
2. Blot WJ, McLaughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 1999, 26:2-8.
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
4. Morales CP, Souza RF, Spechler SJ: Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002, 360:1587-1589.
5. Campbell SL, Khosravi-Far R, Rossman KL, et al.: Increasing complexity of Ras signaling. Oncogene 1998, 17:1395-1413.
6. Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995, 270:16483-16486.
7. Souza RF, Shewmake K, Terada LS, Spechler SJ: Acid exposure activates the mitogen activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002, 122:299-307.
8. Souza RF, Shewmake K, Beer DG, et al.: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000, 60:5767-5772.
9. Souza RF, Shewmake K, Pearson S, et al.: Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol 2004, 287:G743-G748.
10. Sommerer F, Vieth M, Markwarth A, et al.: Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 2004, 23:554-558.
11. Haigh CR, Attwood SE, Thompson DG, et al.: Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003, 124:615-625.
12. Todisco A, Ramamoorthy S, Witham T, et al.: Molecular mechanisms for the antiapoptotic action of gastrin. Am J Physiol Gastrointest Liver Physiol 2001, 280:G298-G307.
13. Harris JC, Clarke PA, Awan A, et al.: An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004, 64:1915-1919.
14. El-Serag H, Aguirre TV, Davis S, et al.: Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004, 99:1877-1883.
15. Jaiswal K, Tello V, Lopez-Guzman C, et al.: Bile salt exposure causes phosphatidylinositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line. Surgery 2004, 136:160-168.
16. Stoler DL, Chen N, Basik M, et al.: The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci U S A 1999, 96:15121-15126
17. Maley CC, Galipeau PC, Li X, et al.: advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004, 64:3414-3427.
18. Wong DJ, Paulson TG, Prevo LJ, et al.: p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001, 61:8284-8289.
19. Maley CC, Galipeau PC, Li X, et al.: The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004, 64:7629-7633.
20. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791.
21. Morales CP, Lee EL, Shay JW: In situ hybridization for the detection of telomerase RNA in the progression fryom Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998, 83:652-659.
22. Shammas MA, Koley H, Beer DG, et al.: Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology 2004, 126:1337-1346.
23. Couvelard A, Paraf F, Gratio V, et al.: Angiogenesis in the neoplastic sequence of Barrett's esophagus: correlation with VEGF expression. J Pathol 2000, 192:14-18.
24. Auvinen MI, Sihvo EIT, Ruohtula T, et al.: Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002, 20:2971-2979.
25. Möbius C, Stein HJ, Becker I, et al.: Vascular endothelial growth factor expression and neovascularization in Barrett's carcinoma. World J Surg 2004, 28:675-679.
26. Beck F: The role of Cdx genes in the mammalian gut. Gut 2004, 53:1394-1396.
27. Phillips RW, Frierson HF, Moskaluk CA: Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003, 27:1442-1447.
28. Moons LMG, Bax DA, Kuipers EJ, et al.: The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004, 57:1063-1068.